Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Juni 2025 07:00 ET | Quelle: Quell TX

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease AstraZeneca exercises option to license the first candidate from the IBD joint research...
18. November 2024 04:00 ET | Quelle: Quell TX

Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress preclinical and clinical development of the selected...
22. Oktober 2024 07:00 ET | Quelle: Quell TX

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses

London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,...